Search
Corbus Pharmaceuticals Holdings Inc
CRBPAdd to Watchlist
10.170USD
+0.430+4.41%
Close 08-07 16:00（ET）Quotes delayed by 15 min
179.11MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-07The current earnings forecast score of Corbus Pharmaceuticals Holdings Inc is 9.00, ranking 17 out of 387 in the Biotechnology & Medical Research industry. The average price target is 39.00, with a high of 53.00 and a low of 28.00.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
36.556
Target Price
+275.31%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Corbus Pharmaceuticals Holdings Inc
CRBP
10
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Corbus Pharmaceuticals Holdings Inc's expected revenue for the next quarter?
Corbus Pharmaceuticals Holdings Inc's expected revenue is 1.67M.
What is Corbus Pharmaceuticals Holdings Inc's price target?
Analysts forecast that Corbus Pharmaceuticals Holdings Inc's price target is USD 39.00, with the highest forecast at USD 53.00 and the lowest forecast at USD 28.00.
How have Corbus Pharmaceuticals Holdings IncCRBP's recent earnings per share performed?
The market expectation was USD -1.81, while Corbus Pharmaceuticals Holdings IncCRBP's earnings per share (EPS) for the previous quarter was USD -1.23. EPS for the next quarter is expected at USD -1.05.
What is the analyst rating for Corbus Pharmaceuticals Holdings Inc?
Based on the ratings of Corbus Pharmaceuticals Holdings Inc's stock from 10 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.